Skip to content

The Female Health Dietary Intervention Study

Treatment of PCOS (Polycystic Ovary Syndrome)in Morbidly Obese Women - A Randomized Controlled Prospective Dietary Intervention Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00779571
Acronym
FEMIN
Enrollment
61
Registered
2008-10-24
Start date
2008-10-31
Completion date
2012-02-29
Last updated
2014-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity, Polycystic Ovary Syndrome

Keywords

Polycystic Ovary Syndrome, Morbid Obesity, Type 2 DM, Coronary heart disease

Brief summary

This study has two phases: 1. In phase 1 of the study (8 weeks),the effect of two different low calorie diets on manifestations of PCOS, including risk factors for the metabolic syndrome and cardiovascular risk profile will be compared. 2. In phase 2 the long term effect (next 44 weeks) on sustained weight-loss and the above mentioned parameters will be compared and evaluated.

Detailed description

Weight loss is an important and effective treatment of morbidly obese women with PCOS. Effective weight reduction will improve manifestations of PCOS and risk factors for developing type 2 diabetes and coronary heart diseases. We compare the effect of two isocaloric low calorie diets (LCD), - one powder-based shake-diet and a fiber rich diet on the above mentioned parameters. In addition we want to compare the weight-maintenance effect the next 44 weeks of two different follow-up programs: A usual care- and a lifestyle-program.

Interventions

BEHAVIORALCrispbread

8 week low calorie diet

Sponsors

Oslo University Hospital
CollaboratorOTHER
The Hospital of Vestfold
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
19 Years to 38 Years
Healthy volunteers
No

Inclusion criteria

* Woman (European Caucasian) * PCOS * BMI = or \> 35

Exclusion criteria

* Cushing syndrome * Adrenal hyperplasia * Androgen-producing tumors * Anovulation caused by hyperprolactinemia * Pregnancy, breast feeding * Use of oral contraceptives/hormone treatment/insulin-sensitizing agents

Design outcomes

Primary

MeasureTime frame
Weight lossOne year

Secondary

MeasureTime frame
Improvement of PCOS, diabetes type 2- and coronary heart disease-risk factorsone year

Countries

Norway

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026